Rezubio Pharmaceuticals advanced RZ-520 into Phase I after receiving IND clearances from both the FDA and China’s National Medical Products Administration (NMPA). The company says dosing is underway in a Phase I trial in healthy volunteers for chronic respiratory diseases. The dual regulatory clearance accelerates the start of clinical evaluation and reduces timeline risk for a cross-market development plan. For respiratory pipeline competition, RZ-520 adds another early-stage candidate as companies continue to explore mechanisms that go beyond symptom management. The next catalyst will be early safety, tolerability, and pharmacokinetic profiling in healthy volunteers, setting the stage for later studies in patient populations.